Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial

Top Cited Papers
Open Access
Abstract
Neurocognition is severely impaired in patients with schizophrenia1,2 independent of phase of illness.3,4 While these impairments may appear prior to the onset of psychosis,5-7 their severity in patients with chronic schizophrenia is about 1.58-10 to 2.011 SDs lower than the healthy population. Neurocognitive impairment is a central clinical feature of schizophrenia, because it is strongly associated with functional outcomes.12,13

This publication has 68 references indexed in Scilit: